Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04260802
Other study ID # OCEL-01
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date October 6, 2020
Est. completion date September 30, 2026

Study information

Verified date November 2023
Source Ocellaris Pharma, Inc.
Contact Study Director: Ocellaris Pharma, Inc
Phone 3176517036
Email choruspharma@lists.lilly.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will investigate OC-001 as monotherapy, and in combination with an anti-Programmed Cell Death Protein-1 (PD-1) or anti-Programmed Cell Death Ligand-1 (PD-L1) Antibody inhibitor, in various cancer types


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date September 30, 2026
Est. primary completion date March 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Have histological or cytological evidence of a diagnosis of selected cancer types that is locally advanced and/or metastatic 1. Have the presence of evaluable disease for the Phase 1b part of the study 2. Have the presence of evaluable and measurable disease for the Phase 2a part of the study 3. The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have failed to provide clinical benefit for their disease or patients who have refused standard treatments. 2. Cancer treatment and type criteria: - Have received at least 1 but no more than 4 prior systemic therapies for locally advanced or metastatic disease (e.g., hormonal, cytotoxic, etc.) for the following cancer types, for Phase 1b: - Triple Negative Breast Cancer (TNBC): Must have recurrent/refractory TNBC, defined as any breast cancer that expresses less than (?)1% estrogen receptor (ER), ? 1% progesterone receptor (PR), and is Human Epidermal Growth Factor Receptor 2 (Her2) negative. Must have failed at least one chemotherapy regimen. - Gastric Cancer: Must have failed a platinum-containing chemotherapy regime. - Cervical Cancer: Must have failed at least one chemotherapy regimen. - Ovarian Cancer: Must have failed a platinum-containing chemotherapy regimen but not be platinum refractory. - Hepatocellular Cell Carcinoma (HCC): May have failed unlimited liver local therapies. - Sarcoma: Must have failed at least one prior chemotherapy regimen. - Squamous Cell Carcinoma of Head and Neck (SCCHN): Must have failed a platinum-containing chemotherapy regiment. Must have failed a previous immune checkpoint inhibitor. - Bladder Cancer: Must have failed a platinum-containing chemotherapy regiment. Must have failed a previous immune checkpoint inhibitor. - Non Small Cell Lung Cancer (NSCLC): Must have failed a platinum-containing chemotherapy regimen or Immuno Oncology (IO) agent in the first line. Must have failed a previous immune checkpoint inhibitor. Must not have any history of tumors that test positive for epidermal growth factor receptor (EGFR), Receptor Tyrosine Kinase (ROS1) , Anaplastic Lymphoma Kinase (ALK) mutations or ALK fusions or any other mutations for which tyrosine kinase inhibitors are available. - Renal Cell Carcinoma (RCC): Must have failed at least one prior systemic therapy. Must have failed a previous IO agent. - Urothelial Cancer: Must have failed at least one prior systemic therapy. Must have failed a previous IO agent. - Merkel Cell: Must have failed at least 1 prior systemic therapy for advanced disease and may have failed a previous IO agent. - Squamous Cell Carcinoma of the Skin: Must have failed at least 1 prior systemic therapy for advanced disease and may have failed a previous IO agent. 3. For Phase 2a: Must have histological or cytological confirmation of a solid tumor that is locally advanced or metastatic. At least one cancer type will be selected amongst the ones evaluated in the Phase 1b part of the study. 4. Have adequate organ function 5. Have a performance status (PS) of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale 6. Have discontinued cytotoxic therapy, biologic therapy, immunotherapy, radiotherapy, and cancer-related hormonal therapy at least 21 days prior to study enrollment 7. Are recovered or recovering from the acute adverse effects of any chemotherapy, biologic, therapy, immunotherapy, cancer-related hormonal therapy, or radiotherapy 8. Patients who have had major surgery must be fully recovered and greater than (=)4 weeks post-operative 9. Men with partners of child-bearing potential or women with child-bearing potential must agree to use a medically approved contraceptive method during and for at least 12 weeks following the last dose of study drug (e.g., intrauterine device (IUD), birth control pills, or barrier method) 10. Women of child-bearing potential must have a negative serum pregnancy test documented 11. Have an estimated life expectancy of at least 3 months Exclusion Criteria: 1. Have symptomatic central nervous system (CNS) metastasis. Patients with treated CNS metastases are eligible for this study if they are asymptomatic and off of corticosteroids for a minimum of 7 days. Patients with primary brain tumors are not eligible 2. Have a history of major organ transplant (e.g., heart, lungs, liver, and kidney) or an autologous or allogeneic hematopoietic stem cell transplant 3. Females who are pregnant or nursing 4. Have known, symptomatic acquired immuno deficiency syndrome (AIDS) or active hepatitis A, B or C 5. Previous treatment-related, severe (=Grade 3) Adverse Event (AE) or any neurologic or ocular AE while receiving an IO agent 6. Active or prior documented autoimmune disease within the past 2 years Patients with vitiligo, Grave's disease or psoriasis not requiring systemic treatment within the past 2 years are eligible 7. Active or prior documented inflammatory bowel disease 8. History of tuberculosis, interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required corticosteroid therapy 9. Receipt of live attenuated vaccination within 28 days prior 10. Current or prior use of immunosuppressive medication within 28 days prior 11. Are currently enrolled in another clinical study of an investigational medicinal product 12. Have a second primary malignancy that may affect the interpretation of results 13. Are unwilling or unable to participate in, or do not have tissue adequate for a tumor biopsy

Study Design


Related Conditions & MeSH terms

  • Bladder Cancer
  • Cancer
  • Carcinoma
  • Carcinoma, Merkel Cell
  • Carcinoma, Squamous Cell
  • Cervical Cancer
  • Gastric Cancer
  • Hepatocellular Carcinoma
  • Locally Advanced Malignant Neoplasm
  • Locally Advanced Solid Tumor
  • Merkel Cell Carcinoma
  • Metastatic Cancer
  • Neoplasm Metastasis
  • Neoplasms
  • Neoplasms, Second Primary
  • Non Small Cell Lung Cancer
  • Ovarian Cancer
  • Renal Cell Carcinoma
  • Sarcoma
  • Squamous Cell Carcinoma
  • Squamous Cell Carcinoma of Head and Neck
  • Triple Negative Breast Cancer
  • Triple Negative Breast Neoplasms
  • Urothelial Carcinoma
  • Urothelial Neoplasm

Intervention

Drug:
OC-001
Monotherapy in Phase 1b
OC-001 in Combination
Anti-PD-1/anti-PD-L1 Ab administered per approved prescribing schedule, in Phase 2a

Locations

Country Name City State
Canada Cross Cancer Institute Edmonton Alberta
Canada Jewish General Hospital - Clinical Research Unit Montreal Quebec
Canada Centre hospitalier de l'Université de Montréal (CHUM) Montréal Quebec
Canada Ottawa Hospital Cancer Centre (OHRI) Ottawa Ontario
Canada Princess Margaret Hospital Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
Ocellaris Pharma, Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with a Dose Limiting Toxicity (DLT) in Phase 1b A Dose-Limiting Toxicity (DLT) is defined as an Adverse Event (AE) that is likely related to the study medication or combination, and fulfills any one of the criteria identified in the Common Terminology Criteria for Adverse Events (CTCAE, Version 5) Baseline through Cycle 1 (Day 28)
Primary Number of participants with any Serious Adverse Event or Treatment-Emergent Adverse Event in Phase 2a Number of participants with any Serious Adverse Event or Treatment-Emergent Adverse Event in Phase 2a Baseline up to two years
Secondary Area Under the OC-001 Plasma Concentration Time Curve (AUC) in Phase 1b After single and multiple dose administration Baseline through 12 weeks
Secondary Maximum Observed OC-001 Concentration (Cmax) in Phase 1b After single and multiple dose administration Baseline through 12 weeks
Secondary Time to reach OC-001 Cmax (Tmax) in Phase 1b Time of maximum concentration observed Baseline through 12 weeks
Secondary Minimum Observed OC-001 Concentration (Cmin) in Phase 1b After single and multiple dose administration Baseline through 12 weeks
Secondary Overall Response Rate (ORR) in Phase 2a In combination with an anti-PD-1 or anti-PD-L1 antibody Baseline up to two years
Secondary Progression Free Survival (PFS) in Phase 2a In combination with an anti-PD-1 or anti-PD-L1 antibody Baseline up to two years
Secondary Duration of Response (DOR) in Phase 2a In combination with an anti-PD-1 or anti-PD-L1 antibody Baseline up to two years
Secondary Time to Response (TTR) in Phase 2a In combination with an anti-PD-1 or anti-PD-L1 antibody Baseline up to two years
Secondary Disease Control Rate (DCR) in Phase 2a In combination with an anti-PD-1 or anti-PD-L1 antibody Baseline up to two years
Secondary Overall Survival (OS) in Phase 2a In combination with an anti-PD-1 or anti-PD-L1 antibody Baseline up to two years
Secondary One-Year Survival Rate in Phase 2a In combination with an anti-PD-1 or anti-PD-L1 antibody Baseline up to two years
Secondary Maximum Observed OC-001 Concentration (Cmax) in Phase 2a In combination with an anti-PD-1 or anti-PD-L1 antibody Baseline through 12 weeks
Secondary Minimum Observed OC-001 Concentration (Cmin) in Phase 2a In combination with an anti-PD-1 or anti-PD-L1 antibody Baseline through 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients